Teva Pharmaceuticals USA, Inc. is recalling 30,360 packages of Isotretinoin Capsules (the generic version of Accutane) because the medication may be too strong (superpotent) or too weak (subpotent). The recall affects certain 30 mg and 40 mg prescription packs distributed in Florida, Ohio, Puerto Rico, and Mississippi. Using a medication with incorrect potency can lead to either decreased effectiveness in treating severe acne or an increased risk of side effects from taking too much medicine.
The capsules may contain more or less of the active ingredient than specified on the label. Subpotent medication may fail to treat the underlying condition, while superpotent medication could expose patients to a higher dose of the drug than intended, potentially leading to dose-related adverse effects.
You have 2 options:
Recall #: D-0445-2026; Manufactured for Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054.
Recall #: D-0446-2026; Manufactured for Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054.
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.